Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00756470 · ClinicalTrials.gov registry record · Phase 2
Phase II Neoadjuvant in Inflammatory Breast Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00756470: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00756470 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00756470, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how well lapatinib taken alone, followed by taking lapatinib with paclitaxel, and then taking lapatinib with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC75) works to help to control Inflammatory Breast Cancer (IBC). The safety of this drug combination will also be studied.
Interventions
- DRUG Cyclophosphamide
- DRUG 5-Fluorouracil (5-FU)
- DRUG Paclitaxel
- DRUG Lapatinib
- DRUG Epirubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-10 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00756470
The ClinicalTrials.gov registry entry for NCT00756470 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00756470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00756470 about?
NCT00756470 is a clinical study titled "Phase II Neoadjuvant in Inflammatory Breast Cancer". The goal of this clinical research study is to learn how well lapatinib taken alone, followed by taking lapatinib with paclitaxel, and then taking lapatinib with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC75) works to help to control Inflammatory Breast Cancer (IBC). The safety of this dru...
What is the current status of trial NCT00756470?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2008-10. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00756470?
The interventions under investigation include: Cyclophosphamide (DRUG), 5-Fluorouracil (5-FU) (DRUG), Paclitaxel (DRUG), Lapatinib (DRUG), Epirubicin (DRUG).
Who is sponsoring clinical trial NCT00756470?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.